LOS ANGELES, August 14, 2018 /PRNewswire/ --
GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP.PA),
an immuno-oncology biotechnology company focused on innovative
treatments based on the company's proprietary platforms, announced
today the Chief Executive Officer, Dr. Raymond W. Urbanski, will present at the Wedbush
PacGrow Healthcare Conference on Wednesday,
August 15, at 1:50pm.
Dr. Urbanski's presentation will provide a corporate overview
and highlight the company's proprietary technology platforms. These
innovative platforms include the tri- and tetra-specific natural
killer cell engagers (TriKEs and TetraKEs) as well as their
bi-specific antibody drug conjugates. In addition, Dr. Urbanski
will provide an update to their current clinical and preclinical
programs.
Dr. Urbanski said, "We are very excited to present at the
Wedbush PacGrow Healthcare Conference. Conferences such as this
gives us the opportunity to engage with leading institutional
investors and interact with other global companies. It also allows
us to further demonstrate that GT Biopharma is at the forefront of
immune-oncology therapeutics."
A webcast of the conference presentation will be available on
the company website at gtbiopharma.com after the conference.
About GT Biopharma, Inc.:
GT Biopharma, Inc. is a biotechnology company focused on
innovative drugs for the treatment of cancer. GT's most advanced
oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific
recombinant fusion protein-drug conjugate targeting CD19 and CD22
on lymphoma and leukemia cells with a modified form of diphtheria
toxin as its cytotoxic dru payload. OXS-1550 targets cancer cells
expressing the CD19 receptor or the CD22 receptor or both
receptors. When OXS-1550 binds to cancer cells, the cancer cells
internalize the drug and are killed due to the action of cytotoxic
payload. OXS-1550 has demonstrated success in early human clinical
trials in patients with relapsed/refractory B-cell lymphoma or
leukemia. In addition, GTs TriKE platform will address a number of
cancer types. The TriKE and TetraKE product candidates are
single-chain, tri- and tetra-specific scFv recombinant fusion
proteins composed of the variable regions of the heavy and light
chains (or heavy chain only) of anti-CD16 antibodies, wild-type or
a modified form of IL-15 and the variable regions of the heavy and
light chains of an antibody designed to precisely target a specific
tumor antigen. We utilize the NK stimulating cytokine human IL-15
as a crosslinker between the two scFvs which is designed to provide
a self-sustaining signal leading to the proliferation and
activation of NK cells thus enhancing their ability to kill cancer
cells mediated by antibody-dependent cell-mediated cytotoxicity
(ADCC).
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the payment of dividends, marketing and distribution
plans, development activities and anticipated operating results.
Factors which could cause actual results to differ materially from
these forward-looking statements include such factors as the
Company's ability to accomplish its business initiatives,
significant fluctuations in marketing expenses and ability to
achieve and expand significant levels of revenues, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Company website:
http://www.GTBiopharma.com
Media Contact:
+1-800-304-9888
SOURCE GT Biopharma Inc.